Company DMS Swiss Exchange
Stocks
OXDGM
FR0000063224
Advanced Medical Equipment & Technology
Business description: DMS
- radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities;
- development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
Products and services are marketed primarily by exclusive retailers.
Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Sales by Activity: DMS
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
DMS Imaging | 36.27M | 35.27M | 42.15M | 46.07M | 49.97M |
DMS Biotech | 691K | - | - | - | - |
Geographical breakdown of sales: DMS
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Europe | 29.51M | 23.88M | 26.41M | 26.95M | 24.8M |
North & South America | 2.36M | 3.74M | 7.45M | 7.99M | 8.48M |
IEC | - | - | 1.49M | 1.07M | 7.12M |
Asia | 2.13M | 4.19M | 2.86M | 4.81M | 3.77M |
Middle East | 1.26M | 953K | 1.89M | 2.02M | 3.76M |
Africa | 1.26M | 1.25M | 1.59M | 2.64M | 1.52M |
Oceania | 440K | 361K | 456K | 580K | 516K |
Unallocated | - | 898K | - | - | - |
Executive Committee: DMS
| Manager | Title | Age | Since |
|---|---|---|---|
Samuel Sancerni
CEO | Chief Executive Officer | 53 | 2022-07-17 |
Valérie Pugnalon
DFI | Director of Finance/CFO | - | 2021-12-31 |
Swan Tuffery
CTO | Chief Tech/Sci/R&D Officer | - | 2018-12-31 |
Jérôme Delanoe
COO | Chief Operating Officer | - | - |
| Investor Relations Contact | - | - |
Composition of the Board of Directors: DMS
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Sancerni
CHM | Chairman | 53 | 2022-07-17 |
Julien Delpech
BRD | Director/Board Member | 52 | 2025-06-15 |
| Director/Board Member | - | 2023-07-23 | |
| Director/Board Member | - | 2023-07-23 | |
Tim Yang
BRD | Director/Board Member | - | - |
Vladislav Tcaci
BRD | Director/Board Member | 38 | - |
| Director/Board Member | 56 | - |
Company details: DMS
Diagnostic Medical Systems
9 Avenue du canal Philippe Lamour
30660, Gaillargues-Le-Montueux
+33 4 66 29 09 07
http://www.dms-imaging.com
Group companies: DMS
| Name | Category and Sector |
|---|---|
Biotechnology
|
Medical Imaging Systems
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.84% | +5.24% | -13.34% | -15.70% | 14.02B | |
| +4.81% | -6.82% | +38.55% | -8.85% | 3.9B | |
| +1.81% | +11.70% | -36.35% | -53.93% | 1.27B | |
| +1.98% | +9.99% | -35.86% | -42.87% | 1.18B | |
| -4.57% | -3.84% | +37.31% | +107.77% | 1.16B | |
| +1.35% | +5.63% | -45.42% | - | 952M | |
| +17.03% | +10.93% | +29.15% | +103.79% | 500M | |
| -1.79% | +1.39% | +68.29% | - | 329M | |
| +0.36% | +2.02% | -59.27% | +221.90% | 265M | |
| Average | +2.24% | +1.42% | -1.88% | +44.59% | 2.62B | |
| Weighted average by Cap. | +0.66% | +2.16% | -4.41% | -6.19% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
